Search Results for "Donepezil Vs Memantine"
Original Source: Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
The trial will examine whether pharmacological treatment with donepezil, memantine or combination of memantine and donepezil is any better than a placebo (dummy) treatment in people with Alzheimer's disease who have reached the moderate to severe stage of illness. Using a double blind design, where neither the investigators nor participants know who is receiving which treatment, participants will be randomly assigned to one of these four treatment groups (donepezil and memantin...
Matching Channels
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles'...
Matching News
Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, whi...
CHMP shakes head at Qsiva and memantine/donepezil combo
The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted negative opinions for Vivus's weight loss drug Qsiva, and a combination pill of memantine and...
Forest looks to evergreen Namenda through Adamas deal for fixed-dose donepezil combo
Forest Laboratories has paid $65 million up front to license Adamas Pharmaceuticals' proprietary fixed-dose combination (FDC) of memantine and donepezil in the US, giving Forest an opportunity to ext...
Acrescent memantine/donepezil regulatory update
Forest, Adamas partner for fixed-dose Alzheimer's combo
Forest Laboratories Inc. (NYSE:FRX) and Adamas Pharmaceuticals Inc. (Emeryville, Calif.) partnered to develop and commercialize Adamas' Arimenda (ADS-8704) in the U.S. to treat moderate to severe Alzh...
Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer's
Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for...
Matching PubMed Articles
Discontinuing donepezil or starting memantine for Alzheimer's disease.
To the Editor: In the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO) study, Howard and coauthors (March 8 issue)(1) found that the magnitude of benefit, as assessed with th...
Discontinuing donepezil or starting memantine for Alzheimer's disease.
To the Editor: In the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO) study, Howard and coauthors (March 8 issue)(1) found that the magnitude of benefit, as assessed with th...
Discontinuing donepezil or starting memantine for Alzheimer's disease.
To the Editor: In the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO) study, Howard and coauthors (March 8 issue)(1) found that the magnitude of benefit, as assessed with th...
Background. Since donepezil and memantine are currently used for treating Alzheimer's disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use....
Background/Aims: A large multicenter trial of donepezil 23 mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer's disease allowed patients taking concomitant memantine. We evaluated the...
